Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: anticancer therapeutics - SignalRx Pharmaceuticals

Drug Profile

Research programme: anticancer therapeutics - SignalRx Pharmaceuticals

Alternative Names: Delta-PI3K/BRD4 inhibitor - SignalRx; Dual PI3K inhibitors - SignalRx; Pan-PI3K/BRD4 inhibitor - SignalRx; PI3K/BRAF dual inhibitor - SignalRx; PI3K/CDK4-6/BRD4 inhibitor programme; PI3K/CDK4-6/BRD4 inhibitors - SignalRx; PI3K/HDAC dual inhibitor - SignalRx; PI3K/MEK dual inhibitor - SignalRx; PI3K/OTHER dual inhibitor - SignalRx; PI3K/PARP dual inhibitor - SignalRx; SF 2506; SF 2523; SF 2535; SF 2558HA; SF 2626; SF 5000; SRX 2523; SRX 2558; SRX 2626; SRX 3636; SRX 5000; SRX-3207

Latest Information Update: 16 Jul 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Indiana University School of Medicine
  • Developer SignalRx Pharmaceuticals
  • Class Pyrones; Small molecules; Thiophenes
  • Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors; BRD4 protein inhibitors; Cyclin-dependent kinase inhibitors; DNA cytosine 5 methyltransferase inhibitors; Histone deacetylase inhibitors; Isocitrate dehydrogenase 1 inhibitors; Mitogen-activated protein kinase kinase inhibitors; Phosphatidylinositol 3 kinase delta inhibitors; Poly(ADP-ribose) polymerase inhibitors; Proto oncogene protein b raf inhibitors; Ras signal transduction pathway inhibitors; Wnt protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 10 Jul 2018 SignalRx Pharmaceuticals has patent protection for thienopyranones scaffold in USA
  • 23 Feb 2018 Preclinical development is ongoing in USA (SignalRx Pharmaceuticals pipeline, February 2018)
  • 28 Dec 2017 No recent reports of development identified for preclinical development in Cancer in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top